Enlivex Announces Upcoming Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 02, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the...
Enlivex Strengthens Management Team with the Appointment of Biotech Industry Veteran Einat Galamidi, M.D., as Vice President, Medical
February 22, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Dr. Galamidi joins Enlivex after 10 years at Gamida Cell Ltd., where she most recently served as Vice President of Clinical Development At Gamida Cell, Dr. Galamidi led clinical development for...
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
November 10, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Enlivex to Present at the ARDS Drug Development Summit 2021
July 14, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, July 14, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer
June 15, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Enlivex Announces Upcoming Virtual Investor Conference Participations
March 09, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares
February 18, 2021 08:00 ET
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...
Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update
February 03, 2021 07:55 ET
|
Enlivex Therapeutics Ltd
Phase II (16 patients treated, 9/16 (56%) with severe illness, 7/16 (44%) with critical illness, follow-up period of 28 days post-AllocetraTM treatment) 0/16 (0%) mortality on day-28 ...
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors
November 17, 2020 08:18 ET
|
Enlivex Therapeutics Ltd
* Dr. Schwartz Served as ArQule’s Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 * Nes Ziona, Israel, Nov. ...
Enlivex: After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients
October 13, 2020 09:28 ET
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry of...